How could disclosing incidental information from whole-genome sequencing affect patient behavior?

Personalized Medicine

Volumn 10, Issue 4, 2013, Pages 377-386

  Christensen, Kurt D ^a   Green, Robert C ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LABORATORY FOR MOLECULAR MEDICINE   (United States)

Author keywords

contextual factor; health behavior; incidental finding; whole genome sequencing

Indexed keywords

MITOCHONDRIAL DNA;

ALZHEIMER DISEASE; BEHAVIOR CHANGE; BENEFICENCE; CANCER RISK; COLORECTAL CANCER; CONSANGUINITY; DISEASE PREDISPOSITION; EMOTION; FAMILY HISTORY; FIRST DEGREE RELATIVE; FOLLOW UP; GENE SEQUENCE; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEALTH BEHAVIOR; HEALTH EDUCATOR; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITY; HUMAN; HUMAN GENOME; INCIDENTAL FINDING; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; LEADERSHIP; LIFESTYLE MODIFICATION; LONG TERM CARE; MEDICAL INFORMATION; MEDICAL RESEARCH; PATIENT PREFERENCE; PERSONAL AUTONOMY; POLICY; PRIORITY JOURNAL; PROGENY; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; STRESS MANAGEMENT; WHOLE GENOME SEQUENCING;

EID: 84878935062     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.24     Document Type: Review

References (80)

1. Lander ES. Initial impact of the sequencing of the human genome. Nature 470(7333), 187-197 (2011).
2. Gilissen C, Hoischen A, Brunner H, Veltman J. Unlocking Mendelian disease using exome sequencing. Genome Biol. 12(9), 228 (2011).
3. Wolf SM, Lawrenz FP, Nelson CA et al. Managing incidental findings in human subjects research: analysis and recommendations. J. Law Med. Ethics 36(2), 219-248 (2008).
4. Meacham MC, Starks H, Burke W, Edwards K. Researcher perspectives on disclosure of incidental findings in genetic research. J. Empir. Res. Hum. Res. Ethics 5(3), 31-41 (2010).
5. McBride CM, Koehly LM, Sanderson SC, Kaphingst KA. The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behaviors? Annu. Rev. Public Health 31(1), 89-103 (2010).
6. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study. Alzheimer Dis. Assoc. Disord. 22(1), 94-97 (2008).
7. Taylor DH, Cook-Deegan RM, Hiraki S, Roberts JS, Blazer DG, Green RC. Genetic testing for Alzheimer's and long-term care insurance. Health Aff. 29(1), 102-108 (2010).
8. de Viron S, van der Heyden J, Ambrosino E, Arbyn M, Brand A, Van Oyen H. Impact of genetic notification on smoking cessation: systematic review and pooled-analysis. PLoS ONE 7(7), e40230 (2012).
9. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genome wide profiling to assess disease risk. N. Engl. J. Med. 364(6), 524-534 (2011).
10. Marteau TM, French DP, Griffin SJ et al. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst. Rev. 10, CD007275 (2010).
11. Christensen KD, Roberts JS, Uhlmann WR et al. How does pleiotropic information affect health behavior changes? Initial results from the REVEAL study, a randomized trial of genetic testing for Alzheimer's disease risk. Presented at: 2010 ACMG Annual Clinical Genetics Meeting. Albuquerque, NM, USA, 24-28 March 2010.
12. Christensen KD, Roberts JS, Uhlmann WR et al. The psychological impact of learning about APOE-cardiovascular disease associations during genetic risk assessment for Alzheimer's disease: findings from the REVEAL study. Alzheimers Dement. 6(4 Suppl. 1), S96-S96 (2010).
13. Green RC, Berg JS, Berry GT et al. Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet. Med. 14(4), 405-410 (2012).
14. Becker MH, Janz NK. Behavioral science perspectives on health hazard/health risk appraisal. Health Serv. Res. 22(4), 537-551 (1987).
15. Rosenstock IM. Historical origins of the health belief model. Health Educ. Monogr. 2(4), 328-335 (1974).
16. Matzger H, Kaskutas LA, Weisner C. Reasons for drinking less and their relationship to sustained remission from problem drinking. Addiction 100(11), 1637-1646 (2005).
17. West R, Sohal T. 'Catastrophic' pathways to smoking cessation: findings from national survey. BMJ 332(7539), 458-460 (2006).
18. Ferguson SG, Shiffman S, Gitchell JG, Sembower MA, West R. Unplanned quit attempts-results from a US sample of smokers and ex-smokers. Nicotine Tob. Res. 11(7), 827-832 (2009).
19. Resnicow K, Page SE. Embracing chaos and complexity: a quantum change for public health. Am. J. Public Health 98(8), 1382-1389 (2008).
20. Fabsitz RR, McGuire A, Sharp RR et al. Ethical and practical guidelines for reporting genetic research results to study participants. Circ. Cardiovasc. Genet. 3(6), 574-580 (2010).
21. Downing NR, Williams JK, Daack-Hirsch S, Driessnack M, Simon CM. Genetics specialists' perspectives on disclosure of genomic incidental findings in the clinical setting. Patient Educ. Couns. 90(1), 133-138 (2013).
22. Wright C, Burton H, Hall A et al. Next Steps in the Sequence. The Implications of Whole Genome Sequencing for Health in the UK. PHG Foundation, Cambridge, UK (2011).
23. McGuire AL, Lupski JR. Personal genome research: what should the participant be told? Trends Genet. 26(5), 199-201 (2010).
24. Berg JS, Khoury MJ, Evans JP. Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet. Med. 13(6), 499-504 (2011).
25. Institute of Medicine. Integrating Large-Scale Genomic Information into Clinical Practice: Workshop Summary. The National Academies Press, Washington, DC, USA (2012).
26. Janz NK, Becker MH. The health belief model: a decade later. Health Educ. Q. 11(1), 1-47 (1984).
27. Linnenbringer E, Roberts JS, Hiraki S, Cupples LA, Green RC. 'I know what you told me, but this is what I think:' perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet. Med. 12(4), 219-227 (2010).
28. Audrain-Mcgovern J, Hughes C, Patterson F. Effecting behavior change: awareness of family history. Am. J. Prev. Med. 24(2), 183-189 (2003).
29. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet. Med. 10(1), 19-32 (2008).
30. Collins RE, Wright AJ, Marteau TM. Impact of communicating personalized genetic risk information on perceived control over the risk: a systematic review. Genet. Med. 13(4), 273-277 (2011).
31. Biesecker LG. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet. Med. 14(4), 393-398 (2012).
32. Murphy J, Scott J, Kaufman D, Geller G, Leroy L, Hudson K. Public expectations for return of results from large-cohort genetic research. Am. J. Bioeth. 8(11), 36-43 (2008).
33. Harris ED, Ziniel SI, Amatruda JG et al. The beliefs, motivations, and expectations of parents who have enrolled their children in a genetic biorepository. Genet. Med. 14(3), 330-337 (2012).
34. Zikmund-Fisher BJ, Angott A, Ubel P. The benefits of discussing adjuvant therapies one at a time instead of all at once. Breast Cancer Res. Treat. 129(1), 79-87 (2011).
35. Zikmund-Fisher BJ, Fagerlin A, Ubel PA. A demonstration of 'less can be more' in risk graphics. Med. Decis. Making 30(6), 661-671 (2010).
36. Ruffin MT, Nease DE Jr, Sen A et al. Effect of preventive messages tailored to family history on health behaviors: the family healthware impact trial. Ann. Fam. Med. 9(1), 3-11 (2011).
37. Petty RE, Cacioppo JT. The elaboration likelihood model of persuasion. In: Advances in Experimental Social Psychology. Berkowitz L (Ed.). Academic Press, NY, USA, 124-205 (1986).
38. Ringold D. Boomerang effects in response to public health interventions: some unintended consequences in the alcoholic beverage market. J. Consumer Policy 25(1), 27-63 (2002).
39. Brehm JA. Theory of Psychological Reactance. John Wiley & Sons, CA, USA (1966).
40. Marteau TM, Senior V, Humphries SE et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am. J. Med. Genet. A 128A(3), 285-293 (2004).
41. Richards M. Families, kinship and genetics. In: The Troubled Helix: Social and Psychological Implications of the New Human Genetics. Marteau T, Richards M (Eds). Cambridge University Press, Cambridge, NY, USA, 249-273 (1996).
42. Nelkin D, Lindee MS. The DNA Mystique: the Gene as a Cultural Icon. University of Michigan, MI, USA (2004).
43. Roberts JS. Surveying customer responses to personal genetic services. Presented at: The American Society of Human Genetics 62nd Annual Meeting. San Francisco, CA, USA, 6-10 November 2012.
44. Resnicow K, McMaster F. Motivational Interviewing: moving from why to how with autonomy support. Int. J. Behav. Nutr. Phys. Act. 9(1), 19 (2012).
45. Shiloh S. Illness representations, self-regulation, and genetic counseling: a theoretical review. J. Genet. Couns. 15(5), 325-337 (2006).
46. Baumeister RF. The self. In: The Handbook of Social Psychology. Gilbert DT, Fiske ST, Lindzey G (Eds). McGraw-Hill, NY, USA. 680-740 (1998).
47. Steele CM. The psychology of self-affirmation: sustaining the integrity of the self. In: Advances in Experimental Social Psychology. Berkowitz L (Ed.). Academic Press, CA, USA, 261-302 (1988).
48. Etchegary H, Perrier C. Information processing in the context of genetic risk: implications for genetic-risk communication. J. Genet. Couns. 16(4), 419-432 (2007).
49. Rochman B. Test your DNA for diseases-no doctor required. Time, 23rd October (2012).
50. Janssens AC, Gwinn M, Bradley LA, Oostra BA, van Duijn CM, Khoury MJ. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am. J. Hum. Genet. 82(3), 593-599 (2008).
51. Berg JS, Adams M, Nassar N et al. An informatics approach to analyzing the incidentalome. Genet. Med. 15(1), 36-44 (2013).
52. Bankhead CR, Brett J, Bukach C et al. The impact of screening on future health-promoting behaviours and health beliefs: a systematic review. Health Technol. Assess. 7(42), 1-92 (2003).
53. Strecher VJ, Kreuter MW. The psychosocial and behavioral impact of health risk appraisals. In: Psychosocial Effects of Screening for Disease Prevention and Detection. Croyle RT (Ed.). Oxford University Press, NY, USA, 126-143 (1995).
54. McGuire AL, Burke W. An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA 300(22), 2669-2671 (2008).
55. Secretary's Advisory Committee on Genetics, Health and Society. Genetics Education and Training. Department of Health & Human Services, Washington, DC, USA (2011).
56. Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet. Med. 5(2), 70-76 (2003).
57. Archibald AD, Hickerton CL, Jaques AM, Wake S, Cohen J, Metcalfe SA. 'It's about having the choice': stakeholder perceptions of population-based genetic carrier screening for fragile X syndrome. Am. J. Med. Genet. A 161(1), 48-58 (2013).
58. Tarini BA. Storage and use of residual newborn screening blood spots: a public policy emergency. Genet. Med. 13(7), 619-620 (2011).
59. Roser MA. State sued over babies' blood. Austin American-Statesman, 13th March (2009).
60. Sangha KK, Dircks A, Langlois S. Assessment of the effectiveness of genetic counseling by telephone compared with a clinic visit. J. Genet. Couns. 12(2), 171-184 (2003).
61. Witte K, Allen M. A meta-analysis of fear appeals: implications for effective public health campaigns. Health Educ. Behav. 27(5), 591-615 (2000).
62. McBride CM, Curry SJ, Grothaus LC, Rosner D, Louie D, Wagner EH. Use of self-help materials and smoking cessation among proactively recruited and volunteer intervention participants. Am. J. Health Promot. 12(5), 321-324 (1998).
63. Tzelepis F, Paul CL, Walsh RA, McElduff P, Knight J. Proactive telephone counseling for smoking cessation: meta-analyses by recruitment channel and methodological quality. J. Natl Cancer Inst. 103(12), 922-941 (2011).
64. Christensen KD, Roberts JS, Zikmund-Fisher BJ, Kardia SL, Mcbride CM, Green RC. Self-referral to genetic susceptibility testing for Alzheimer's disease: implications for uptake and responses to results. Presented at: The 2013 ACMG Annual Clinical Genetics Meeting. Phoenix, AZ, USA, 19-23 March 2013.
65. Manne S, Fasanella N, Connors J, Floyd B, Wang H, Lessin S. Sun protection and skin surveillance practices among relatives of patients with malignant melanoma: prevalence and predictors. Prev. Med. 39(1), 36-47 (2004).
66. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous melanoma by skin self-examination. J. Natl Cancer Inst. 88(1), 17-23 (1996).
67. Kohane IS, Hsing M, Kong SW. Taxonomizing, sizing, and overcoming the incidentalome. Genet. Med. 14(4), 399-404 (2012).
68. Rew L, Kaur M, McMillan A, Mackert M, Bonevac D. Systematic review of psychosocial benefits and harms of genetic testing. Issues Ment. Health Nurs. 31(10), 631-645 (2010).
69. Green RC, Roberts JS, Cupples LA et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N. Engl. J. Med. 361(3), 245-254 (2009).
70. Witte K. Putting the fear back into fear appeals: the extended parallel process model. Commun. Monogr. 59(4), 329-349 (1992).
71. Eichler EE, Flint J, Gibson G et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat. Rev. Genet. 11(6), 446-450 (2010).
72. McBride CM, Bryan AD, Bray MS, Swan GE, Green ED. Health behavior change: can genomics improve behavioral adherence? Am. J. Public Health 102(3), 401-405 (2012).
73. Colditz GA, Wei EK. Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality. Annu. Rev. Public Health 33(1), 137-156 (2012).
74. Beery TA, Williams JK. Risk reduction and health promotion behaviors following genetic testing for adult-onset disorders. Genet. Test. 11(2), 111-123 (2007).
75. Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann GJ. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet. Med. 11(4), 265-278 (2009).
76. Grant RW, O'Brien KE, Waxler JL et al. Personalized genetic risk counseling to motivate diabetes prevention: a randomized trial. Diabetes Care 36(1), 13-19 (2013).
77. Morris JC. Dementia update 2005. Alzheimer Dis. Assoc. Disord. 19(2), 100-117 (2005).
78. Alamian A, Rouleau I, Simard J, Dorval M. Use of dietary supplements among women at high risk of Hereditary Breast and Ovarian Cancer (HBOC) tested for cancer susceptibility. Nutr. Cancer 54(2), 157-165 (2006).
79. Vernarelli JA, Roberts JS, Hiraki S, Chen CA, Cupples LA, Green RC. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am. J. Clin. Nutr. 91(5), 1402-1407 (2010).
80. The President's Council on Bioethics. The Changing Moral Focus of Newborn Screening: an Ethical Analysis by the President's Council on Bioethics. The President's Council on Bioethics, Washington, DC, USA (2008).